Price target
7.830.000.00%
The 6 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of KPTI is 1.81 USD — it has increased by 1.51% in the past 24 hours. Watch Karyopharm Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Karyopharm Therapeutics Inc. stocks are traded under the ticker KPTI.
KPTI stock has risen by 3.06% compared to the previous week, the month change is a −79.49% fall, over the last year Karyopharm Therapeutics Inc. has showed a −61.24% decrease.
We've gathered analysts' opinions on Karyopharm Therapeutics Inc. future price: according to them, KPTI price has a max estimate of 15.00 USD and a min estimate of 3.00 USD. Watch KPTI chart and read a more detailed Karyopharm Therapeutics Inc. stock forecast: see what analysts think of Karyopharm Therapeutics Inc. and suggest that you do with its stocks.
KPTI reached its all-time high on Dec 8, 2014 with the price of 735.08 USD, and its all-time low was 1.80 USD and was reached on Jul 31, 2026. View more price dynamics on KPTI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KPTI stock is 13.41% volatile and has beta coefficient of 2.14. Track Karyopharm Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Karyopharm Therapeutics Inc. there?
Today Karyopharm Therapeutics Inc. has the market capitalization of 45.82 M, it has decreased by −1.25% over the last week.
Yes, you can track Karyopharm Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Karyopharm Therapeutics Inc. is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
KPTI earnings for the last quarter are −2.32 USD per share, whereas the estimation was −1.37 USD resulting in a −69.14% surprise. The estimated earnings for the next quarter are −1.00 USD per share. See more details about Karyopharm Therapeutics Inc. earnings.
Karyopharm Therapeutics Inc. revenue for the last quarter amounts to 33.43 M USD, despite the estimated figure of 32.19 M USD. In the next quarter, revenue is expected to reach 33.62 M USD.
KPTI net income for the last quarter is −67.02 M USD, while the quarter before that showed −22.39 M USD of net income which accounts for 0.00% change. Track more Karyopharm Therapeutics Inc. financial stats to get the full picture.
No, KPTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 17, 2026, the company has 228 employees. See our rating of the largest employees — is Karyopharm Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Karyopharm Therapeutics Inc. EBITDA is −82.05 M USD, and current EBITDA margin is −61.90%. See more stats in Karyopharm Therapeutics Inc. financial statements.
Like other stocks, KPTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Karyopharm Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Karyopharm Therapeutics Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Karyopharm Therapeutics Inc. stock shows the sell signal. See more of Karyopharm Therapeutics Inc. technicals for a more comprehensive analysis.